Sign in Register Sign out My account

05-Oct-2021 - Last updated on 05-Oct-2021 at 10:08 GMT

Related tags: Cold chain, Kenya, Marken, cell and gene therapy

It has expanded its cold chain services and packaging solutions, whle new storage locations in Kenya and Ghana are in the pipeline. The idea is to provide increased flexibility and global access for customers, including in emerging markets like South Korea and Sub-Saharan Africa.

The UPS subsidiary sees the investments as especially critical for cell and gene therapy (CGT) developers, where there is increased innovation enabled by mRNA, CAR-T, and viral vectors. and huge growth forecast for that segment. The US Food and Drug Administration (FDA) is expected to approve 10 to 20 CGT products per year by 2025.  

Ariette van Strien, president of Marken, told BioPharma-Reporter: “Expanding our GMP network, including cold chain, is critical for cell and gene therapy developers as it allows them to reach patients in previously unreached populations. ​We’re excited about our planned expansion into Ghana and Kenya as it can help with temporary and permanent storage of mRNA vaccines or even cell and gene therapies to these regions.”​

Marken’s ongoing and planned investments include:

In addition to GMP storage, the company will be able to track cell and gene therapy, compassionate use, and early access program shipments from its Ukraine facility.

“This new control center, combined with the existing control center in Durham, NC, US, will enhance 24/7/365 global monitoring of all complex shipments, including cell and gene shipments.”​

Copyright - Unless otherwise stated all contents of this web site are © 2022 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Related topics: Bio Developments, Emerging Markets, Cell & Gene Therapies, Analytical (technologies & services)

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...